Páez A, Archundia A, Méndez CR, Rodríguez E, López MR, Masso F, Aceves JL, Flores L, Montaño LF

Idioma: Español
Referencias bibliográficas: 26
Paginas: 99-104
Archivo PDF: 412.12 Kb.

RESUMEN

El objetivo de este trabajo era determinar si en las células endoteliales aisladas de aneurismas abdominales aórticos existe alguna condición basal pre-establecida que incremente los mecanismos efectores inmunes y, por ende, nos pueda dar alguna pista acerca de los mecanismos por los que los aneurismas se perforan. Se aislaron células endoteliales de fragmentos saculares de aneurismas aórticos abdominales perforados; la expresión de diferentes moléculas relacionadas con la respuesta inmune fue analizada por citofluorometría. Los resultados mostraron la presencia de una subpoblación de células ricas en gránulos citoplásmicos, CD105 positiva y antígeno de von Willebrand negativa que mostraba una sobreexpresión de ICAM-1 y de antígeno Fas, pero sin que hubiera cuerpos apoptóticos. Las células endoteliales control obtenidas de regiones sanas de la misma aorta abdominal no mostraron sobreexpresión. En conclusión, creemos que dentro del endotelio que recubre las regiones donde se forman aneurismas, en la aorta abdominal existe una subpoblación de células endoteliales que tienen inhibido el proceso de muerte celular programada y que además se encuentran en un estado de activación proinflamatoria.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Ross R: Atherosclerosis –an inflammatory disease. New Engl J Med 1999; 340: 115-26.

2. Selzman CH, Miller SA, Harken AH: Therapeutic implications of inflammation in atherosclerotic cardiovascular disease. Ann Thorac Surg 2001; 71: 2066-74.

3. Singh K, Bonaa KH, Jacobsen BK, Bjork L, Solberg S: Prevalence of and risk factors for abdominal aortic aneurysms in a population-based study : The Tromso Study. Am J Epidemiol 2001; 154: 236-44.

4. Kontusaari S, Tromp G, Kuivaniemi H, Romanic AM, Prockop DJ: A mutation in the gene for type III procollagen (COL3A1) in a family with aortic aneurysms. J Clin Invest 1990; 86: 1465-73.

5. Bode MK, Soini Y, Melkko J, Satta J, Risteli L, Risteli J: Increased amount of type III pN-collagen in human abdominal aortic aneurysms: evidence for impaired type III collagen fibrillogenesis. J Vasc Surg 2000; 32: 1201-7.

6. Ohtahara A, Santo Y, Ogino K: Infective abdominal aortic aneurysm. Heart 2001; 86: 126.

7. Goodall S, Crowther M, Hemingway DM, Bell PR, Thompson MM: Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 2001; 104: 304-9.

8. Tung WS, Lee JK, Thompson RW: Simultaneous analysis of 1176 gene products in normal human aorta and abdominal aortic aneurysms using a membrane-based complementary DNA expression array. J Vasc Surg 2001; 34: 143-50.

9. Juvonen J, Surcel HM, Satta J, Teppo AM, Bloigu A, Syrjala H, et al: Elevated circulating levels of inflammatory cytokines in patients with abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 1997; 17: 2843-7.

10. Wolf YG, Bernstein EF: A current perspective on the natural history of abdominal aortic aneurysms. Cardiovasc Surg 1994; 2:16-22.

11. Cassar K, Godden DJ, Duncan JL: Community mortality after ruptured abdominal aortic aneurysm is unrelated to the distance from the surgical centre. Br J Surg 2001; 88:1341-3, 2001.

12. Breslow JL: Genetic differences in endothelial cells may determine atherosclerosis susceptibility. Circulation 2000; 102: 5-6.

13. Dong ZM, Wagner DD: Leukocyte-endothelium adhesion molecules in atherosclerosis. J Lab Clin Med 1998; 132: 369-75.

14. Muller WA, Randolph GJ: Migration of leukocytes across endothelium and beyond: molecules involved in the transmigration and fate of monocytes. J Leukoc Biol 1999; 66: 698-704.

15. Prasad KN, Hovland AR, Nahreini P, Cole WC, Hovland P, Kumar B, et al: Differentiation genes: are they primary targets for human carcinogenesis? Exp Biol Med 2001; 226: 805-13.

16. Nagata S: Apoptosis by death factor. Cell 1997; 88: 355-65.

17. Sata M, Walsh K: Oxidized LDL activates Fas-mediated endothelial cell apoptosis. J Clin Invest 1998; 102: 1682-9.

18. Lopez-Marure R, Ventura JL, Sanchez L, Montano LF, Zentella A: Ceramide mimics tumour necrosis factor-alpha in the induction of cell cycle arrest in endothelial cells. Induction of the tumour suppressor p53 with decrease in retinoblastoma/protein levels. Eur J Biochem 2000; 267: 4325-33.

19. Cohen GM: Caspases: the executioners of apoptosis. Biochem J 1997; 326: 1-16.

20. Zornig M, Hueber A, Baum W, Evan G: Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 2001; 1551: F1-37.

21. Yonemasu H, Takashima M, Nishiyama KI, Ueki T, Yao T, Tanaka M, et al: Phenotypical characteristics of undifferentiated carcinoma of the pancreas: a comparison with pancreatic ductal adenocarcinoma and relevance of E-cadherin, alpha catenin and beta catenin expression. Oncol Rep 2001; 8: 745-52.

22. Zelivianski S, Verni M, Moore C, Kondrikov D, Taylor R, Lin MF: Multipathways for transdifferentiation of human prostate cancer cells into neuroendocrine-like phenotype. Biochim Biophys Acta 2001; 1539: 28-43.

23. Takamatsu M, Fujita T, Hotta H: Suppression of serum starvation-induced apoptosis by hepatitis C virus core protein. Kobe J Med Sci 2001; 47: 97-112.

24. Tollefson AE, Toth K, Doronin K, Kuppuswamy M, Doronina OA, Lichtenstein DL, et al: Inhibition of TRAIL-induced apoptosis and forced internalization of TRAIL receptor 1 by adenovirus proteins. J Virol 2001; 175: 8875-7.

25. Aplin AE, Howe A, Alahari SK, Juliano RL: Signal transduction and signal modulation by cell adhesion receptors: the role of integrins, cadherins, immunoglobulin-cell adhesion molecules, and selectins. Pharmacol Rev 1998; 50: 197-263.

26. Aoudjit F, Vuori K: Integrin signaling inhibits paclitaxel-induced apoptosis in breast cancer cells. Oncogene 2001; 20: 4995-5004.